Background. Solid organ transplant recipients (SOTRs) are predisposed to infection due to the need for lifelong immunosuppression, although tools to measure the overall degree of immunosuppression are limited. In this study, we used a novel global cell-mediated immunity (CMI) assay to quantify the degree of immunosuppression and predict subsequent infections.
Organ transplant recipients require lifelong immunosuppression to prevent allograft rejection. The degree of immunosuppression in transplant recipients is variable and likely influenced by multiple factors including age, comorbidity, and immunosuppressive drug doses and levels, as well as other host-related immune factors. Infections are a leading cause of morbidity and mortality in transplant recipients [1] . In the first month posttransplant, infections are commonly the result of technical factors; however, from month 1 and beyond, there is an increased incidence of opportunistic infections (OIs), especially in the first year posttransplant when immunosuppression tends be at its highest. Antimicrobial prophylaxis is often used to prevent OIs from organisms such as cytomegalovirus (CMV) and Pneumocystis jirovecii. However, for many OIs, effective prediction and prevention measures are lacking.
One of the major limitations in the clinical care of transplant patients is our inability to measure the overall degree of immunosuppression in a given patient. For example, in persons infected with human immunodeficiency virus, CD4 + T-cell counts serve as an important benchmark for determining the risk of OIs. Similarly, in transplant patients, a simple laboratory-based measurement of global immunity would potentially allow better risk stratification (as it relates to infection) and result in improved adjustment of both immunosuppression and antimicrobial prophylaxis. Several studies have associated defects in innate and adaptive immunity posttransplant with OIs. Previously studied innate immune factors include Toll-like receptor polymorphisms, natural killer (NK) receptor polymorphisms, and low complement levels [2] [3] [4] . Measurements of the adaptive immune responses such as hypogammaglobulinemia and CD4 + T-cell counts have also been associated with infection [5, 6] . Others have suggested the use of an immunological score to predict infection [7] . In addition, the ImmuKnow assay (Cylex), which measures adenosine triphosphate (ATP) release from CD4 + T cells, has been used in transplantation as a marker of immunity. However, studies associating ATP levels with infections posttransplant have been conflicting [8, 9] . None of the aforementioned assays provide a global view of both innate and adaptive immunity, which may be a better predictor of the likelihood of infection.
In this study, we used a novel global cell-mediated immu-
measures plasma interferon-gamma (IFN-γ) levels after stimulation of whole blood with a combination of antigens designed to stimulate both the innate and adaptive arms of the immune system. A previous study using this assay showed that plasma IFN-γ levels in liver transplant candidates and recipients were significantly lower than in healthy control subjects [10] . We hypothesized that a lower immune response would be associated with subsequent increased infection risk whereas a higher immune response could be protective from infection. Currently, there are no published data that evaluate whether this assay may be predictive of posttransplant infections. Therefore, we performed a prospective observational cohort study in organ transplant recipients using serial measurements of this assay to determine its ability to predict infection.
METHODS

Patient Population
We enrolled consecutive organ transplant recipients within the first month posttransplant. Patients underwent testing with the QFM assay at 1, 3, and 6 months posttransplant. Patients were followed up to 1 year posttransplant for the development of infection. The first measurement was performed at month 1 to simplify enrollment and because infectious complications occurring very early posttransplant are commonly technical or surgically related and not necessarily reflective of the net state of immunosuppression. Patient characteristics, including demographics, type of transplant, underlying disease, immunosuppressive agents, and infections were recorded. Patients were enrolled at the Toronto General Hospital Multi-Organ Transplant Program, which performs >500 transplants annually. Standard prophylaxis for CMV in the transplant program includes 3, 6, and 9 months of valganciclovir for high-risk donor-seropositive/ recipient-seronegative (D + /R -) liver, kidney, and lung recipients, respectively. CMV-seropositive lung recipients and those who receive antithymocyte globulin also get 3 months of valganciclovir prophylaxis. The remaining recipients are monitored by CMV polymerase chain reaction (PCR) for 12 weeks posttransplant. Trimethoprim-sulfamethoxazole prophylaxis is used for 6 months in kidney and liver transplant recipients and lifelong in lung transplant recipients. Liver transplant recipients with high-risk characteristics including multiple operations, massive transfusion, and biliary complications receive fluconazole prophylaxis for 2-4 weeks posttransplant. In lung transplant recipients, antifungal therapy with a mold-active agent is started for 1-3 months if a bronchoalveolar lavage specimen shows the presence of Aspergillus or a positive galactomannan. The study was approved by the University Health Network Research Ethics Board. Informed consent was obtained from all patients.
Laboratory Methods
The QFM assay was used to measure cellular immune responses as per the manufacturer's instructions. In brief, 1 mL of whole blood was collected in a heparinized tube. A lyosphere containing anti-CD3 (T-cell stimulant) and R848 (a Toll-like receptor 7 ligand) was added to the whole blood within 8 hours of collection followed by incubation for 16-24 hours at 37°C after which it was centrifuged to obtain plasma. An enzyme-linked immunosorbent assay (ELISA) for IFN-γ (IU/mL) was performed. For the purposes of the study, plasma was collected and stored at -80°C for batch testing. The assay results were not released to treating physicians and did not influence clinical decisions.
Definitions
Infections were defined according to the American Society of Transplantation (AST) guidelines, which provide infection definitions for use in clinical trials involving organ transplant recipients [11] . In all patients, the presence or absence of an infectious complication was determined by 3 separate study physicians (D. K., A. H., Y. N.), with discrepancies undergoing a group review and adjudication. Bacterial infections included symptomatic urinary tract infections (UTI) with a bacterial isolate present in significant quantity (>10 8 colony-forming units/L). Bacterial pneumonia was included if symptomatic and confirmed by microbiology and/or chest radiography. Fungal infections were included if they met the definition of "proven" or "probable" as per the AST guidelines. Symptomatic CMV disease was defined using previously published definitions and CMV viremia was defined as any quantifiable viral load in a plasma sample (lower limit of quantitation, 137 IU/mL; Roche Cobas AmpliPrep TaqMan Assay) [11] . CMV viral loads were measured as part of routine surveillance in high-risk patients after prophylaxis or if clinically suspected. Posttransplant lymphoproliferative disorders (PTLDs) that were positive for Epstein-Barr virus (EBV) by in situ hybridization and had concurrent detectable EBV plasma viremia were included as an infection-related complication. No routine surveillance for EBV was performed. All kidney transplant patients underwent monthly plasma BK viral load testing till 1 year posttransplant. BK viremia ≥10 000 copies/mL (BK PCR kit 1.0, Altona Diagnostics; lower limit of quantitation, 10 copies/mL) was considered a significant level. This level of viremia was chosen a priori as (1) not all patients with BK viremia underwent kidney biopsy and (2) higher viral loads in the range of 4 log copies/ mL have been associated with BK nephropathy [12, 13] . Fungal infections were defined based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group definitions [14] . A separate subgroup analysis was also performed based on an a priori-defined classification of what were considered OIs. These were defined as any viral, fungal, or mycobacterial infection. Bacterial UTI, bacterial pneumonia, central venous catheter-related bacteremia, and Clostridium difficile colitis were not considered OIs for the purpose of the subgroup analysis.
Statistical Analysis
The primary outcome was the occurrence of infectious complications in the first year posttransplant. The primary analysis was based on assessing the potential predictive value of the assay, as determined by differences in CMI response between patients who had an infection vs those who did not. For this purpose, the month 1 CMI result was assessed for prediction of infections between 1 and 3 months posttransplant; the month 3 CMI result was assessed for predictions of infections between months 3 and 6; and the month 6 CMI result was assessed for prediction between months 6 and 12. Demographics were analyzed using descriptive statistics. Wilcoxon matched-pairs signed-rank test was used to compare continuous paired IFN-γ results. Mann-Whitney U test was used to compare IFN-γ results for independent subgroups of transplant patients. Spearman rank-order test was used to find correlations between continuous variables. All statistical tests were performed using Prism GraphPad version 7 (La Jolla, California) and IBM SPSS version 22.0 (Chicago, Illinois) software. A P value <.05 was considered significant.
RESULTS
Patient Population
We enrolled 151 consecutive organ transplant recipients. Of these 137 patients provided CMI measurements on at least 1 study time point. In this cohort, the median age was 58 (interquartile range [IQR], 47-65) years; transplant types were kidney (32.1%), liver (30.7%), lung (36.5%), and intestinal (1 patient) ( Table 1) . Induction immunosuppression with antithymocyte globulin was given to 40 of 137 (29.2%) patients. The majority of patients were on triple immunosuppression. Prednisone use decreased over time whereas the majority of patients continued use of mycophenolate and a calcineurin inhibitor.
Cell-Mediated Immunity Over Time
In the total cohort, IFN-γ levels were measured at 1, 3, and 6 months posttransplant (Figure 1) . Median levels at month 1 were 11.1 (IQR, 0.84-34.5) IU/mL; at 3 months they increased significantly to 33.7 (IQR, 4.1-110) IU/mL (P = .007 compared with month 1); at 6 months they leveled off and were similar to month 3 (median, 40.0 [IQR, 9.7-99.4] IU/mL; P = .53 compared to month 3). Absolute lymphocyte counts were not significantly associated with IFN-γ levels at any timepoint (data not shown), but dosages of immunosuppression showed association (see below).
Cell-Mediated Immunity and Immunosuppression
Patients who received induction immunosuppression with antithymocyte globulin had lower IFN-γ levels at month 3 than those who received basiliximab (median, 14.7 vs 66.5 IU/mL, P = .005). We analyzed the association of IFN-γ levels with prednisone dosing, mycophenolate doses, and tacrolimus levels ( Table 2) . Prednisone dose was negatively correlated with IFN-γ levels at all timepoints (P < .05 for all timepoints). Mycophenolate doses were also inversely correlated with IFN-γ levels at month 1 (ρ = -0.233, P = .025) and month 6 (ρ = -0.282, P = .022). Tacrolimus levels also showed some correlation but did not reach statistical significance.
Cell-Mediated Immunity and Transplant Type
CMI increased over time in all transplant recipients. However, lung transplant patients (n = 50) had IFN-γ levels that were significantly lower compared to kidney and liver transplant recipients at all 3 time points (month 1, P = .002; month 3, P = .0005; and month 6, P = .03) (Supplementary Figure 1) . Differences among the organ groups seemed to be attributable to the degree of immunosuppressive medications. For example, at month 3 where the difference in IFN-γ levels between lung and nonlung Figure 2) . The majority of infections were bacterial during the first time period (1-3 months) posttransplant and consisted primarily of UTIs and pneumonia. However, after the third posttransplant month, viral infections predominated, especially CMV (Supplementary Figure 3) . Three patients developed PTLD in the first year and 7 patients developed BK viremia ≥10 000 copies/mL. The predictive values of IFN-γ levels were compared between patients with and without infections using the month 1 CMI (to predict infections between 1 and 3 months), month 3 CMI (to predict infections between 3 and 6 months) and month 6 CMI (to predict infections between 6 and 12 months). Patients with infection had significantly lower IFN-γ values than those without infection (Figure 2 ). Median month 1 IFN-γ levels were 5.52 IU/mL in patients with infection vs 13.6 IU/mL in patients with no subsequent infection (P = .040); month 3 values were 8.06 IU/mL and 39.6 IU/mL in the 2 groups, respectively (P = .050). Similarly, month 6 levels were 14.2 IU/mL in the group with subsequent infection vs 57.8 IU/mL in the group with no subsequent infection (P = .006). Patients with the extreme lowest IFN-γ levels had substantially higher risks of infection. Of the total number of IFN-γ measurements (n = 322) performed in the study, approximately one-third were ≤10 IU/mL. Using this as a cutoff value, odds ratios for the likelihood of infection were calculated at each timepoint. For month 1, patients with IFN-γ ≤10 IU/mL had an odds ratio of 2.26 (95% CI, 0.97-5.25; P = .055) for the development of subsequent infection. Similarly, for months 3 and 6, the odds ratios for subsequent infection, using the same cutoff value, were 3.88 (95% CI, 1.55-9.70; P = .005) and 2.78 (95% CI, 1.09-7.09; P = .034), respectively. In patients who had a very high IFN-γ result (≥200 IU/mL), subsequent infections were seen in 0 of 7 (0%) patients from months 1 to 3; 1 of 13 (7.7%) patients from months 3 to 6; and 2 of 9 (22.2%) patients from months 6 to 12. These infections were Pseudomonas UTI, orolabial herpes simplex, and PTLD with EBV viremia in an EBV D + /R -patient. At months 3 and 6, the association of CMI with infection was primarily driven by OIs. Using only OI as an endpoint, IFN-γ levels were significantly lower in those with OIs vs no OIs (P = .024 and P = .014, respectively) ( Figure 3) . We also did a subgroup analysis of symptomatic CMV disease as an outcome during 1-12 months posttransplant. A total of 14 of 137 (10.2%) patients developed CMV disease. As the number of outcomes was low, only the month 1 IFN-γ result was analyzed in relation to subsequent CMV disease at any time in the first year. Month 1 IFN-γ results were significantly lower in those who went on to have CMV disease than those without (P = .0004; Supplementary Figure 4) .
Rejection Outcomes
Twenty-five of 137 (18.2%) patients had 29 episodes of biopsy-proven rejection from months 1 to 12 posttransplant. Ten Data expressed as correlation coefficient (rho) and P value using Spearman test. Equivalent doses of MMF and MPS were calculated [18] .
Prednisone doses, MMF/MPS doses, and tacrolimus levels are analyzed as continuous variables.
Abbreviations: CMI, cell-mediated immunity; MMF/MPS, mycophenolate mofetil/mycophenolate sodium. episodes occurred between 1 and 3 months, 7 episodes occurred between 3 and 6 months, and 12 episodes between 6 and 12 months (Supplementary Figure 3) . No significant differences were noted between IFN-γ levels in patients who developed rejection vs those who had no rejection episode (data not shown).
DISCUSSION
We performed a prospective observational cohort study using a global immune monitoring assay to predict infectious complications during the first year posttransplant. We found that overall immune function, as measured by the assay, increased over time posttransplant and also depended on type of transplant as well as induction and maintenance immunosuppression. Overall, the assay was broadly predictive of the likelihood of subsequent infectious complications, with patients with low IFN-γ values being at highest risk of subsequent infection. The best predictive value was observed at the 6-month time point, although predictive utility was observed at all 3 time points. The subgroup of patients with very low IFN-γ values (≤10 IU/mL; representing approximately one-third of patients) was the subset identified to be at particularly increased risk of subsequent infection. We also found that subsequent CMV disease was also inversely correlated with the IFN-γ response. We used a composite endpoint of "all infection"-microbiologically proven bacterial, viral, and fungal infectionconsistent with the non-pathogen-specific immunological measurement assay that we used. Monitoring for infection was done independent of IFN-γ testing and all patients were closely followed at our transplant center and reported symptoms to the transplant coordinator assigned to them, thereby making it unlikely that any infections were missed. We also focused on symptomatic infection, which is generally more clinically relevant than asymptomatic colonization. Viral infections such as CMV and BK are likely overrepresented due to standard monitoring protocols; however, current guidelines in transplant patients do not recommend monitoring for other infections such as UTI or pneumonia. We showed that infections were primarily bacterial from month 1 to month 3, whereas viral infections predominated from 3 to 12 months posttransplant. This is consistent with descriptions of infections in the transplant literature. There are limited data in the literature of the use of this specific CMI assay to predict infection. In a cross-sectional study of 29 liver transplant recipients and 212 healthy volunteers, transplant recipients had significantly lower values [10] . Patients who were several years posttransplant tended to have higher IFN-γ values than those who were early posttransplant. Subsequently, a prior study of 75 liver transplant recipients using this assay only in the first posttransplant month showed a significant association with infection and early rejections [15] . In contrast to these previous studies, we chose to start IFN-γ monitoring at 1 month posttransplant because many infections prior to that are related to postsurgical and technical complications rather than specific immune defects, thereby confounding the results. Interestingly, we found that the month 6 timepoint was the most predictive; this may be more relevant because this is the time when specific antiviral and antifungal prophylaxis strategies may be discontinued. A low CMI at this time could predict future infection. This was particularly evident in patients with a negative or very low test result. For example, we showed that an IFN-γ value of ≤10 IU/mL would increase the likelihood of infection by 2-to 3-fold depending on the timepoint. However, it should be noted that some patients with very high responses still had infectious complications, although these infections were in small numbers. Also, we did not find a correlation of the CMI assay with rejection although this may be due to the low numbers of biopsy-proven rejections seen after 1 month posttransplant.
Although the CMI assay we used is not pathogen specific, interestingly the month 1 IFN-γ value was predictive of CMV disease during the year, suggesting that nonspecific as well as CMV-specific T cells along with others such as NK cells are critical for the control of this virus. Pathogen-specific CMI assays for CMV are under development and could potentially be used in conjunction with the current assay.
An important finding in the study was the relationship of CMI to immunosuppression. Indeed, use of polyclonal immunoglobulin for induction therapy had the greatest potency in reducing CMI levels. Prednisone dosing showed a significant association with IFN-γ levels. Prednisone has broad activity against a variety of cell populations; similarly, mycophenolate prevents purine synthesis, thereby decreasing proliferation of both B and T cells [16] . Similar to Sood et al [10] , we did not find an association of CMI with tacrolimus levels. Tacrolimus is a calcineurin inhibitor primarily affecting T-cell function, although multiple cell types likely contribute to the IFN-γ measured by the assay.
Our study has some limitations that reflect both the nature of the assay as well as the study design. The assay measures a combined IFN-γ output from whole blood and it is not possible to determine the proportional contribution of innate vs adaptive immunity. However, the CMI assay used in this study has certain advantages in that it requires only a simple ELISA method and only 1 mL volume of whole blood. We only measured 3 timepoints posttransplant. However, these timepoints were chosen to reflect times at which patients may return for follow-up and based on likelihood of OIs [17] . We also did not have sufficient endpoints for acute rejection to determine whether this assay is useful to predict rejection. This would be the subject of further study. Finally, there was significant diversity in the magnitude of IFN-γ response, and some patients with very high responses still went on to have infectious complications. This has important implications when trying to understand the potential clinical utility of the assay and how global immune responses may not always be correlated with pathogen-specific immune responses.
In summary, we show that non-pathogen-specific CMI testing may have clinical utility to predict the risk of infections posttransplant. Further studies could help define optimal cutoffs and the effect of interventions (such as immunosuppression modulation) based on assay results.
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